Table 1: Sales by Segment 1 Table 2: Sales by Geographic Area 2 Table 3: Sales of Key Products/Franchises 3 - 7 Table 3a: Supplemental Sales Reconciliation 8 Table 4: Condensed Consolidated Statement of Earnings - QTD 9 Table 5: Non-GAAP Adjusted Operational Sales Growth - QTD 10 Table 6: Non-GAAP Adjusted Net Earnings 11 Table 7: Non-GAAP IBT and R&D Expense by Segment - QTD 12 Table 8: Non-GAAP P&L Reconciliation 13 First Quarter 2024 Other Financial Disclosures Table of Contents -- 1 of 14 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) 2024 2023 Total Operations Currency Sales to customers by segment of business Innovative Medicine (1) U.S. 7,612 7,023 8.4 8.4 - International 5,950 6,390 (6.9) (4.0) (2.9) 13,562 13,413 1.1 2.5 (1.4) Innovative Medicine excluding COVID-19 Vaccine (1) U.S. 7,612 7,023 8.4 8.4 - International 5,925 5,643 5.0 8.3 (3.3) 13,537 12,666 6.9 8.3 (1.4) MedTech U.S. 4,008 3,759 6.6 6.6 - International 3,813 3,722 2.4 6.1 (3.7) 7,821 7,481 4.5 6.3 (1.8) U.S. 11,620 10,782 7.8 7.8 - International 9,763 10,112 (3.4) (0.3) (3.1) Worldwide 21,383 20,894 2.3 3.9 (1.6) U.S. 11,620 10,782 7.8 7.8 - International 9,738 9,365 4.0 7.4 (3.4) Worldwide excluding COVID-19 Vaccine (1) 21,358 $ 20,147 6.0 % 7.6 (1.6) Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. (1) Refer to supplemental sales information schedules FIRST QUARTER Percent Change -- 2 of 14 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) 2024 2023 Total Operations Currency Sales to customers by geographic area U.S. 11,620 $ 10,782 7.8 % 7.8 - Europe 5,163 5,590 (7.6) (7.7) 0.1 Western Hemisphere excluding U.S. 1,194 1,076 11.0 21.3 (10.3) Asia-Pacific, Africa 3,406 3,446 (1.1) 5.0 (6.1) International 9,763 10,112 (3.4) (0.3) (3.1) Worldwide 21,383 $ 20,894 2.3 % 3.9 (1.6) Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) 2024 2023 Total Operations Currency Sales to customers by geographic area (ex. COVID-19 Vaccine) U.S.* 11,620 $ 10,782 7.8 % 7.8 - Europe(1) 5,138 4,843 6.1 6.0 0.1 Western Hemisphere excluding U.S.* 1,194 1,076 11.0 21.3 (10.3) Asia-Pacific, Africa* 3,406 3,446 (1.1) 5.0 (6.1) International 9,738 9,365 4.0 7.4 (3.4) Worldwide 21,358 $ 20,147 6.0 % 7.6 (1.6) Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. (1) Refer to supplemental sales information schedules *No COVID-19 Vaccine sales Percent Change FIRST QUARTER Percent Change FIRST QUARTER -- 3 of 14 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER INNOVATIVE MEDICINE SEGMENT (2) 2024 2023 Reported Operational (1) Currency IMMUNOLOGY US 2,453 $ 2,448 0.2% 0.2% - Intl 1,794 1,664 7.9% 11.0% -3.1% WW 4,247 4,112 3.3% 4.6% -1.3% REMICADE US 266 276 -3.9% -3.9% - US Exports (3) 27 41 -32.7% -32.7% - Intl 141 170 -17.2% -14.2% -3.0% WW 434 487 -10.9% -9.9% -1.0% SIMPONI / SIMPONI ARIA US 254 271 -6.2% -6.2% - Intl 299 266 12.4% 20.0% -7.6% WW 554 537 3.0% 6.8% -3.8% STELARA US 1,396 1,451 -3.8% -3.8% - Intl 1,055 993 6.2% 8.2% -2.0% WW 2,451 2,444 0.3% 1.1% -0.8% TREMFYA US 509 406 25.4% 25.4% - Intl 299 234 27.9% 31.5% -3.6% WW 808 640 26.3% 27.6% -1.3% OTHER IMMUNOLOGY US 0 3 * * - Intl 0 0 - - - WW 0 3 * * - INFECTIOUS DISEASES US 324 392 -17.4% -17.4% - Intl 497 1,193 -58.4% -58.5% 0.1% WW 821 1,586 -48.3% -48.3% 0.0% COVID-19 VACCINE US 0 0 - - - Intl 25 747 -96.6% -96.7% 0.1% WW 25 747 -96.6% -96.7% 0.1% EDURANT / rilpivirine US 8 9 -10.9% -10.9% - Intl 315 271 16.6% 15.7% 0.9% WW 323 280 15.7% 14.8% 0.9% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 314 378 -16.9% -16.9% - Intl 104 99 5.5% 5.5% 0.0% WW 418 477 -12.3% -12.3% 0.0% OTHER INFECTIOUS DISEASES US 2 5 -68.8% -68.8% - Intl 52 77 -32.8% -30.6% -2.2% WW 53 82 -35.1% -33.1% -2.0% % Change -- 4 of 14 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER % Change 2024 2023 Reported Operational (1) Currency NEUROSCIENCE US 1,054 978 7.8% 7.8% - Intl 749 826 -9.3% -4.4% -4.9% WW 1,803 1,804 0.0% 2.2% -2.2% CONCERTA / Methylphenidate US 41 70 -41.2% -41.2% - Intl 136 136 -0.1% 4.5% -4.6% WW 177 206 -14.1% -11.1% -3.0% INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA US 765 713 7.2% 7.2% - Intl 292 331 -11.8% -8.7% -3.1% WW 1,056 1,044 1.2% 2.2% -1.0% SPRAVATO US 191 111 71.5% 71.5% - Intl 34 20 76.1% 74.8% 1.3% WW 225 131 72.2% 72.0% 0.2% OTHER NEUROSCIENCE US 58 84 -31.1% -31.1% - Intl 287 339 -15.5% -8.4% -7.1% WW 345 423 -18.5% -12.9% -5.6% ONCOLOGY US 2,383 1,889 26.2% 26.2% - Intl 2,430 2,223 9.3% 12.6% -3.3% WW 4,814 4,112 17.1% 18.8% -1.7% CARVYKTI US 140 70 99.8% 99.8% - Intl 16 2 * * * WW 157 72 * * * DARZALEX US 1,464 1,191 22.9% 22.9% - Intl 1,228 1,072 14.5% 19.0% -4.5% WW 2,692 2,264 18.9% 21.0% -2.1% ERLEADA US 285 249 14.1% 14.1% - Intl 404 293 38.0% 40.6% -2.6% WW 689 542 27.0% 28.4% -1.4% IMBRUVICA US 265 270 -1.5% -1.5% - Intl 518 557 -7.0% -5.6% -1.4% WW 784 827 -5.2% -4.3% -0.9% TECVAYLI(4) US 101 57 76.7% 76.7% - Intl 33 6 * * * WW 133 63 * * * ZYTIGA / abiraterone acetate US 9 16 -41.3% -41.3% - Intl 172 229 -24.8% -20.7% -4.1% WW 181 245 -25.9% -22.1% -3.8% OTHER ONCOLOGY(4) US 119 35 * * - Intl 60 64 -6.1% -5.6% -0.5% WW 178 99 80.2% 80.5% -0.3% -- 5 of 14 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER 2024 2023 Reported Operational (1) Currency PULMONARY HYPERTENSION US 766 600 27.5% 27.5% - Intl 283 272 4.1% 10.9% -6.8% WW 1,049 872 20.2% 22.4% -2.2% OPSUMIT US 356 273 30.4% 30.4% - Intl 169 167 0.8% 4.6% -3.8% WW 524 440 19.1% 20.6% -1.5% UPTRAVI US 392 304 29.0% 29.0% - Intl 76 58 30.7% 38.6% -7.9% WW 468 362 29.2% 30.5% -1.3% OTHER PULMONARY HYPERTENSION US 18 23 -24.6% -24.6% - Intl 39 47 -16.9% -1.0% -15.9% WW 56 70 -19.5% -8.9% -10.6% CARDIOVASCULAR / METABOLISM / OTHER US 631 715 -11.7% -11.7% - Intl 197 212 -7.0% -6.8% -0.2% WW 829 927 -10.6% -10.5% -0.1% XARELTO US 518 578 -10.4% -10.4% - Intl - - - - - WW 518 578 -10.4% -10.4% - OTHER US 114 137 -17.1% -17.1% - Intl 197 212 -7.0% -6.8% -0.2% WW 311 349 -11.0% -10.9% -0.1% TOTAL INNOVATIVE MEDICINE US 7,612 7,023 8.4% 8.4% - Intl 5,950 6,390 -6.9% -4.0% -2.9% WW 13,562 $ 13,413 1.1% 2.5% -1.4% See footnotes at end of schedule % Change -- 6 of 14 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER MEDTECH SEGMENT (2) 2024 2023 Reported Operational (1) Currency CARDIOVASCULAR (5) US 1,025 $ 863 18.8% 18.8% - Intl 781 640 22.1% 27.6% -5.5% WW 1,806 1,503 20.2% 22.5% -2.3% ELECTROPHYSIOLOGY US 692 571 21.3% 21.3% - Intl 652 522 24.9% 30.9% -6.0% WW 1,344 1,092 23.0% 25.9% -2.9% ABIOMED US 303 264 15.0% 15.0% - Intl 67 60 12.4% 14.7% -2.3% WW 371 324 14.5% 15.0% -0.5% OTHER CARDIOVASCULAR (5) US 30 28 3.3% 3.3% - Intl 62 58 6.9% 11.5% -4.6% WW 92 87 5.7% 8.8% -3.1% ORTHOPAEDICS US 1,448 1,363 6.2% 6.2% - Intl 892 881 1.3% 2.7% -1.4% WW 2,340 2,245 4.3% 4.8% -0.5% HIPS US 270 241 12.1% 12.1% - Intl 152 149 1.7% 3.3% -1.6% WW 422 390 8.1% 8.7% -0.6% KNEES US 242 226 6.9% 6.9% - Intl 160 142 12.3% 13.1% -0.8% WW 401 368 9.0% 9.3% -0.3% TRAUMA US 504 491 2.8% 2.8% - Intl 261 267 -2.3% -1.1% -1.2% WW 765 757 1.0% 1.4% -0.4% SPINE, SPORTS & OTHER US 432 406 6.5% 6.5% - Intl 320 323 -0.9% 0.9% -1.8% WW 752 729 3.2% 4.0% -0.8% % Change -- 7 of 14 -- REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER 2024 2023 Reported Operational (1) Currency SURGERY US 987 975 1.2% 1.2% - Intl 1,429 1,459 -2.0% 2.3% -4.3% WW 2,416 2,434 -0.7% 1.9% -2.6% ADVANCED US 446 444 0.2% 0.2% - Intl 641 673 -4.7% -0.7% -4.0% WW 1,087 1,118 -2.8% -0.3% -2.5% GENERAL US 542 531 2.1% 2.1% - Intl 788 785 0.3% 4.8% -4.5% WW 1,330 1,316 1.0% 3.7% -2.7% VISION US 547 558 -1.8% -1.8% - Intl 710 743 -4.4% -1.1% -3.3% WW 1,258 1,300 -3.3% -1.4% -1.9% CONTACT LENSES / OTHER US 438 444 -1.4% -1.4% - Intl 472 509 -7.4% -3.1% -4.3% WW 910 953 -4.6% -2.3% -2.3% SURGICAL US 110 114 -3.7% -3.7% - Intl 238 233 2.2% 3.4% -1.2% WW 348 347 0.3% 1.1% -0.8% TOTAL MEDTECH US 4,008 3,759 6.6% 6.6% - Intl 3,813 3,722 2.4% 6.1% -3.7% WW 7,821 $ 7,481 $ 4.5% 6.3% -1.8% * Percentage greater than 100% or not meaningful (1) Operational growth excludes the effect of translational currency (2) Unaudited (3) Reported as U.S. sales (4) See Supplemental Sales Information Schedule (5) Previously referred to as Interventional Solutions % Change Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely -- 8 of 14 -- Schedule 1 2024 2023 Total Operations Currency Innovative Medicine U.S. 7,612 $ 7,023 8.4 % 8.4 - International 5,950 6,390 (6.9) (4.0) (2.9) Worldwide 13,562 13,413 1.1 2.5 (1.4) COVID-19 Vaccine U.S. - - - - - International 25 747 (96.6) (96.7) 0.1 Worldwide 25 747 (96.6) (96.7) 0.1 Innovative Medicine excluding COVID-19 Vaccine U.S. 7,612 7,023 8.4 8.4 - International 5,925 5,643 5.0 8.3 (3.3) Worldwide 13,537 12,666 6.9 8.3 (1.4) Worldwide U.S. 11,620 10,782 7.8 7.8 - International 9,763 10,112 (3.4) (0.3) (3.1) Worldwide 21,383 20,894 2.3 3.9 (1.6) COVID-19 Vaccine U.S. - - - - - International 25 747 (96.6) (96.7) 0.1 Worldwide 25 747 (96.6) (96.7) 0.1 Worldwide U.S. 11,620 10,782 7.8 7.8 - International 9,738 9,365 4.0 7.4 (3.4) Worldwide excluding COVID-19 Vaccine 21,358 $ 20,147 6.0 % 7.6 (1.6) Europe 5,163 $ 5,590 (7.6) % (7.7) 0.1 Europe COVID-19 Vaccine Sales 25 747 (96.6) (96.7) 0.1 Europe excluding COVID-19 Vaccine Sales 5,138 $ 4,843 6.1 % 6.0 0.1 Schedule 2 Full Year Q1 Q2 Q3 Q4 Full Year INNOVATIVE MEDICINE SEGMENT (1) ONCOLOGY TECVAYLI US 12 57 82 93 102 334 INTL 3 6 12 19 24 61 WW 15 63 94 112 126 395 OTHER ONCOLOGY US 144 35 40 50 90 215 INTL 280 64 80 67 58 269 WW 423 99 120 117 148 484 Note: Columns and rows within tables may not add due to rounding (1) Unaudited Percent Change Supplemental Sales Information (Unaudited) (Dollars in Millions) 2022 2023 2023 FIRST QUARTER -- 9 of 14 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers 21,383 $ 100.0 20,894 $ 100.0 2.3 Cost of products sold 6,511 30.4 6,687 32.0 (2.6) Gross Profit 14,872 69.6 14,207 68.0 4.7 Selling, marketing and administrative expenses 5,257 24.6 4,906 23.5 7.2 Research and development expense 3,542 16.6 3,455 16.6 2.5 In-process research and development impairments - - 49 0.2 Interest (income) expense, net (209) (1.0) 14 0.1 Other (income) expense, net (322) (1.5) 6,940 33.2 Restructuring 164 0.8 130 0.6 Earnings/(loss) before provision for taxes on income 6,440 30.1 (1,287) (6.2) Provision for/(Benefit from) taxes on income 1,086 5.1 (796) (3.9) Net earnings/(loss) from Continuing Operations 5,354 $ 25.0 (491) $ (2.3) Net earnings from Discontinued Operations, net of tax - 423 Net earnings/(loss) 5,354 $ (68) $ Net earnings (loss) per share (Diluted/Basic) from Continuing Operations 2.20 $ (0.19) $ Net earnings per share (Diluted) from Discontinued Operations - $ 0.16 $ Average shares outstanding (Diluted/Basic) 2,430.1 2,605.5 * Effective tax rate from Continuing Operations 16.9 % 61.8 % Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1) Earnings before provision for taxes on income from Continuing Operations 7,877 $ 36.8 7,536 $ 36.1 4.5 Net earnings from Continuing Operations 6,580 $ 30.8 6,340 $ 30.3 3.8 Net earnings per share (Diluted) from Continuing Operations 2.71 $ 2.41 $ 12.4 Average shares outstanding (Diluted) 2,430.1 2,634.3 Effective tax rate from Continuing Operations 16.5 % 15.9 % *Basic shares are used to calculate loss per share in the first quarter of 2023 as use of diluted shares when in a loss position would be anti-dilutive (1) See Reconciliation of Non-GAAP Financial Measures. FIRST QUARTER 2024 2023 -- 10 of 14 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Innovative Medicine MedTech Total WW As Reported 1.1% 4.5% 2.3% U.S. 8.4% 6.6% 7.8% International (6.9)% 2.4% (3.4)% WW Currency (1.4) (1.8) (1.6) U.S. - - - International (2.9) (3.7) (3.1) WW Operational 2.5% 6.3% 3.9% U.S. 8.4% 6.6% 7.8% International (4.0)% 6.1% (0.3)% All Other Acquisitions and Divestitures (A&D) 0.0 0.2 0.1 U.S. 0.0 0.2 0.1 International 0.0 0.1 0.0 WW Adjusted Operational Ex A&D 2.5% 6.5% 4.0% U.S. 8.4% 6.8% 7.9% International (4.0)% 6.2% (0.3)% COVID-19 Vaccine 5.8 3.7 U.S. 0.0 0.0 International 12.3 7.7 WW Adjusted Operational Ex A&D & COVID-19 Vaccine 8.3% 6.5% 7.7% U.S. 8.4% 6.8% 7.9% International 8.3% 6.2% 7.4% Adjusted Operational Sales Growth FIRST QUARTER 2024 ACTUAL vs. 2023 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum -- 11 of 14 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) 2024 2023 Net Earnings/(loss) from Continuing Operations, after tax- as reported $5,354 ($491) Pre-tax Adjustments Litigation related - 6,900 Intangible Asset Amortization expense 1,078 1,122 COVID-19 Vaccine related costs 1 9 444 Restructuring related 2 171 130 Medical Device Regulation 3 51 64 Acquisition, integration and divestiture related 148 42 (Gains)/losses on securities (20) 72 IPR&D impairments - 49 Tax Adjustments Tax impact on special item adjustments 4 (229) (1,980) Tax legislation and other tax related 18 (12) Adjusted Net Earnings from Continuing Operations, after tax $6,580 $6,340 Average shares outstanding (Diluted) 2,430.1 2,634.3 Adjusted net earnings per share from Continuing Operations (Diluted) $2.71 $2.41 Operational adjusted net earnings per share from Continuing Operations (Diluted) $2.72 Notes: 1 2 3 4 First Quarter In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expenses of $144 million in the fiscal first quarter of 2024 and $130 million in the fiscal first quarter of 2023 include the termination of partnered and non-partnered program costs and asset impairments. In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expenses of $27 million in the fiscal first quarter of 2024 primarily includes costs related to market and product exits. European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which will be completed during 2024. The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments. -- 12 of 14 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2024 2023 2024 2023 2024 2023 2024 2023 Reported Income Before Tax by Segment From Continuing Operations $ 4,969 4,402 1,520 1,409 (49) (7,098) 6,440 (1,287) % to Sales 36.6% 32.8% 19.4% 18.8% -0.2% -34.0% 30.1% -6.2% Intangible asset amortization expense 698 739 380 383 - - 1,078 1,122 In-process research and development impairments - - - 49 - - - 49 Litigation related - - - - - 6,900 - 6,900 Loss/(gain) on securities (55) 38 22 34 13 - (20) 72 Restructuring related 144 130 27 - - - 171 130 Acquisition, integration and divestiture related 47 - 61 42 40 - 148 42 Medical Device Regulation - - 51 64 - - 51 64 COVID-19 Vaccine related costs 9 444 - - - - 9 444 Adjusted Income Before Tax by Segment From Continuing Operations $ 5,812 5,753 2,061 1,981 4 (198) 7,877 7,536 % to Sales 42.9% 42.9% 26.4% 26.5% 0.0% -0.9% 36.8% 36.1% *Estimated as of 4/16/2024 As Reported Research and development expense $ 2,896 2,778 646 677 3,542 3,455 % to Sales 21.4% 20.7% 8.3% 9.1% 16.6% 16.6% Q1 YTD - Income Before Tax and Research & Development Expense by Segment* Dollars in Millions Innovative Medicine MedTech Unallocated Worldwide Total -- 13 of 14 -- First Quarter March 31, 2024 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation First Quarter March 31, 2024 Non-GAAP Cost of products sold 6,511 $ (1,078) (7) (20) (2) - 5,404 Selling, marketing and admin expenses 5,257 (4) 5,253 Research and development expense 3,542 (18) (27) (7) 3,490 Other (Income) / Expense (322) - - - (130) 20 - - (432) In-process research and development impairments - - - Restructuring 164 (164) - Provision for taxes on income 1,086 148 - - 39 38 (7) 9 2 (18) 1,297 Net Earnings from Continuing Operations 5,354 930 - - 132 110 (13) 42 7 18 6,580 First Quarter April 2, 2023 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation First Quarter April 2, 2023 Non-GAAP Cost of products sold 6,687 $ (1,118) - (23) (206) - 5,340 Selling, marketing and admin expenses 4,906 (7) 4,899 Research and development expense 3,455 (16) (34) (16) 3,389 Other (Income) / Expense 6,940 (4) (6,900) - (26) (72) (222) (284) In-process research and development impairments 49 (49) - Restructuring 130 (130) - Provision for (Benefit from) taxes on income (796) 177 1,622 11 32 5 16 12 105 12 1,196 Net Earnings (Loss) from Continuing Operations (491) 945 5,278 38 98 37 56 52 339 (12) 6,340 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Year to Date In-process research and development impairments Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Tax legislation and other tax related In-process research and development impairments Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Tax legislation and other tax related -- 14 of 14 --